In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Lilly pays $110mm up front plus earn-outs to acquire AurKa Pharma and regain cancer candidate

Executive Summary

Eli Lilly & Co. penned its second oncology acquisition in one week, agreeing to acquire privately held AurKa Pharma Inc. for $110mm up front, plus up to $465mm in regulatory- and sales-based earn-outs.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Acquisition of Private Biotech
    • Payment Includes Cash
    • Full Acquisition
    • Includes Earnout

Related Companies

Advertisement
UsernamePublicRestriction

Register